Answers are grounded in this paper and cite their sources.
Evaluation of: Lockman S, Shapiro RL, Smeaton LM et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356(2), 135–147 (2007). Although single-dose nevirapine given to HIV-infected pregnant women during labor is highly efficacious in preventing intrapartum mother-to-child transmission of HIV, it is associated with the selection of HIV nevirapine resistance mutations, which can compromise the efficacy of subsequent non-nucleosidic reverse transcriptase inhibitor-based regimens. In the context of a perinatal HIV prevention trial where pregnant women were randomized to receive intrapartum nevirapine or placebo, the authors assessed the impact of nevirapine exposure on virologic and immunologic response to nevirapine-based therapy in mothers who initiated therapy in the postpartum period and in their infected infants. Exposure to nevirapine was associated with an increased risk of virologic failure by the 6-month visit after treatment initiation in both women and infants. However, in the subgroup of women who initiated therapy more than 6 months after delivery, this association was not statistically significant. While the increase in CD4+ cell count by the 6-month visit was significantly different according to previous exposure to nevirapine in infants, this was not observed in the women.
No takes yet. Share an insight, caveat, or question.
Lallemant et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: